If youre like me, one of the untold millions who signed up for Amazon Prime years ago strictly for the free two-day shipping, you might not realize some of the other benefits of being a Primer.
SEE ALSO: 11 Things You Can’t Return to Amazon
Oh, I havent been clueless. I knew Prime members had access to free streaming videos and music, as well as Kindle reader freebies and whatnot. As an all-things-Apple person since the late 1980s, I really had no use for any of those bennies. iTunes and a Netflix subscription have met my needs.
So when the yearly fee for Amazon Prime shot up to $99 and my billing cycle hit in May, I started having second thoughts about Primes ROI. Im no longer ordering enough products through Amazon to cover $99 worth of shipping costs. And the one time I needed Amazon video the service failed me.
Top 5 Valued Companies To Buy For 2017: NewStar Financial, Inc.(NEWS)
NewStar Financial, Inc. operates as a commercial finance company in the United States. It provides senior secured cash flow loans, and second lien and unitranche loans to middle market companies for acquisitions, recapitalizations, and refinancing or other general corporate purposes; and senior secured loans to larger middle market companies. The company also offers working capital financing, such as asset-based loans, including revolving lines of credit, and senior secured term loans to asset-intensive companies for acquisitions, recapitalizations, and growth strategies. In addition, it provides first mortgage transitional financing to professional real estate investors and developers to acquire and reposition commercial properties comprising office, multi-family, retail, and industrial properties. Further, the company offers a range of equipment loan and lease financing options to mid-sized companies to fund various equipmen t types consisting of manufacturing, technology, healthcare, transportation, and telecom equipment, as well as it provides investment advisory and asset management services. It serves healthcare, manufacturing and industrial, financial services, energy/chemical services, printing/publishing, business and technology services, auto/transportation, marketing, wholesale distribution, technology, telecommunications, and education, as well as consumer, retail, and restaurant industries. The company was formerly known as Novus Capital, Inc. and changed its name to NewStar Financial, Inc. in June, 2004. NewStar Financial, Inc. was incorporated in 2003 and is based in Boston, Massachusetts.
- [By Lisa Levin] Related AHT 25 Biggest Mid-Day Gainers For Friday Mid-Day Market Update: Hortonworks Drops Following Weak Results; Freshpet Shares Spike Higher Ashford Hospitality Trust's (AHT) CEO Montgomery Bennet on Q2 2016 Results – Earnings Call Transcript (Seeking Alpha) Related NEWS Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs Mid-Morning Market Update: Markets Open Lower; Broadcom Profit Beats Expectations NewStar Financial's (NEWS) CEO Tim Conway on Q2 2016 Results – Earnings Call Transcript (Seeking Alpha)
Top 5 Valued Companies To Buy For 2017: AbbVie Inc.(ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinsons disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics, Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illi! nois.
- [By Ben Levisohn]
Raymond James analyst Christopher Raymond and team sayAbbVie (ABBV) is “not your father’s biotech company” as they initiate coverage with an Outperform rating:
Kevin Hagen for The Wall Street Journal
Initiating coverage of ABBV shares with an Outperform rating and an $82 price target as we think uncertainty over Humira’s intellectual property (IP) creates an opportunity to own this name at a significant discount to its peers before the full extent of the drug’s revenue tail becomes reflected in the stock. Coupling that with a rapidly diversifying portfolio, numerous upcoming value-enhancing catalysts, and a decent dividend yield, we think shares can continue to work higher over the next several quarters.
Not your father’s biotech company. Having spun out of Abbott Laboratories (ABT) in 2013, and based in North Chicago, IL, AbbVie comes with a decidedly different pedigree than most biotechs. Indeed, most investors we speak with tend to lump the company in with large pharma – simply by virtue of this legacy. However, with a growth profile, product offering, and pipeline that is every bit that of a biotech company, we think this name should increasingly be viewed through such a lens…
We think the stock can continue to work from here. While Humira still accounts for ~60% of revenue, AbbVie has made great strides toward diversification (with some seen as smart deals, others – the jury is still out), all of which poise the company for significant catalyst flow, in our view. Coupling that with current mid-teens EPS growth, a dividend yield of ~3.5%, and current P/E of ~13x 2016E EPS, we like the set up here.
Shares of AbbVie are little changed at $64.06 at 3:01 p.m. today, while Abbott Laboratories has declined 0.5% to $42.07.
- [By Ben Levisohn]
After surveying doctors on the preferred hepatitis-C treatments, Baird’s Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in what appears to be a shrinking market. They explain:
- [By Ben Levisohn]
The main conclusions we draw from the abstracts (lacking information about late breakers) is that Gileads dominance of HCV seems secure for the immediate future, with sof/vel (sofosbuvir/velpatasvir) showing impressive efficacy in difficult-to-treat patient subsets. Competitors have early data for their new HCV development efforts (Merck (MRK) [MP], Johnson & Johnson (JNJ) [OP], AbbVie (ABBV)) but will not present new clinical data at this meeting.
Top Managed Healthcare Stocks To Buy Right Now: Express Scripts Holding Company(ESRX)
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. The companys PBM segments products and services include clinical solutions to enhance health outcomes; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services, including design, implementation, and project management for pharmaceutical, biotechnology, and device manufacturers to collect scientific evidence to guide the use of medicines. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2015, the company operated four automated dispensing home delivery pharmacies; one non-automated dispensing home delivery pharmacy; and one non-dispensing home delivery pharmacy maintained for business continuity purpose, as well as several non-dispensing order processing centers, patient contact centers, specialty drug pharmacies, and fertility pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headqua rtered in St. Louis, Missouri.
- [By Monica Gerson]
Express Scripts Holding Company (NASDAQ: ESRX) is expected to post its quarterly earnings at $1.22 per share on revenue of $25.20 billion.
Xerox Corp (NYSE: XRX) is estimated to report its quarterly earnings at $0.23 per share on revenue of $4.24 billion.
- [By Monica Gerson]
Wall Street expects Express Scripts Holding Company (NASDAQ: ESRX) to post its quarterly earnings at $1.22 per share on revenue of $25.20 billion. Express Scripts shares rose 0.30 percent to close at $73.55 on Friday.
Top 5 Valued Companies To Buy For 2017: Amira Nature Foods Ltd(ANFI)
Amira Nature Foods Ltd. engages in processing, distributing, and marketing packaged Indian specialty rice, primarily basmati rice; and other food products. The company provides various types of basmati rice, specialty rice and value add meals, ready-to-eat snacks, ready to heat meals, edible oils, and organic products for retailers under the Amira brand; and non-basmati rice. It also sells bulk commodities, including wheat, barley, legume, maize, sugar, soybean meal, onion, potato, and millets to trading firms. Amira Nature Foods Ltd. sells its products to buyers in the Asia Pacific, the Middle East, Europe, North Africa, and North America; and distributors and retail chains in India. The company was founded in 1915 and is based in Dubai, the United Arab Emirates.
- [By Roberto Pedone]
Another earnings short-squeeze prospect is packaged specialty rice and other food products distributor Amira Nature Foods (ANFI), which is set to release numbers on next Monday after the market close. Wall Street analysts, on average, expect Amira Nature Foods to report revenue of $132.37 million on earnings of 32 cents per share.
The current short interest as a percentage of the float for Amira Nature Foods is extremely high at 26.6%. That means that out of 17.70 million shares in the tradable float, 4.72 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 8.2%, or by 356,000 shares. If the bears get caught pressing their bets into a bullish quarter, then shares of ANFI could easily rip sharply higher post-earnings as the shorts move fast to cover some of their trades.
From a technical perspective, ANFI is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock just recently bounced higher off some near-term support at $15.25 a share. That bounce is starting to push shares of ANFI within range of triggering a near-term breakout trade post-earnings.
If you’re bullish on ANFI, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $17 to $17.98 a share and then above more resistance at $18.52 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 174,102 shares. If that breakout develops post-earnings, then ANFI will set up to re-test or possibly take out its next major overhead resistance levels at $19.86 to $20.29 a share, or even its 52-week high at $25 a share.
I would simply avoid ANFI or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below some key near-term supp
Top 5 Valued Companies To Buy For 2017: Shoe Carnival, Inc.(SCVL)
Shoe Carnival, Inc., together with its subsidiaries, operates as family footwear retailer primarily in the United States. It provides various dress, casual, and athletic footwear products for men, women, and children; and accessories, including socks, belts, shoe care items, handbags, jewelry, scarves, and wallets. As of January 30, 2016, the company operated 405 stores in 34 states and Puerto Rico. It sells its products through online shopping at shoecarnival.com. Shoe Carnival, Inc. was founded in 1978 and is headquartered in Evansville, Indiana.
- [By Jeroen Jongbloed]
Foot Locker (FL) is a retailer of athletic shoes and apparel which operates 3369 stores in the US, Canada, Europe, Australia and New-Zealand. On July 10th 2013, it completed its acquisition of Runners Point Group. In today’s article, I will be looking at FL’s revenue, net income, dividend and valuation. At certain points, I will use DSW, Inc. (DSW) and Shoe Carnival, Inc. (SCVL) for comparison.